Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system

Gl Colombo, S Chimenti, S Di Matteo, Mc Fargnoli, P Frascione, V Silipo, Ketty Peris

Risultato della ricerca: Contributo in rivistaArticolo in rivista

15 Citazioni (Scopus)


Actinic keratosis (AK) is the most common cutaneous malignant neoplasm and its prevalence continues to increase. According to the most recent findings, AK is currently considered the initial stage, in situ, of squamous cell carcinoma. Field-directed therapies for AKs are the preferred treatment since they have the advantage to clear the clinically visible lesions and also subclinical lesions within the cancerous field. We assessed the cost-effectiveness of topical treatments for AKs including 3% diclofenac in 2.5% hyaluronic acid (HA) gel, imiquimod 5% cream and photodynamic therapy with methyl aminolevulinate (MAL-PDT) in the perspective of the Italian Health Care System (SSN). We used a decision tree analytical approach and efficacy data were drawn from published clinical trials. Cost was evaluated from the SSN perspective during a time horizon of 3 months. A responder was defined as a patient with all lesions clinically cleared and showing an excellent cosmetic result. Based on the applied model, the cost per complete responder was calculated. Diclofenac 3% in HA was less expensive (Euro 256) than MAL-PDT (Euro 320) and imiquimod (Euro 342). Effectiveness was similar and better for diclofenac 3% in HA and MAL-PDT (0.813%) in comparison to 0.734% of imiquimod, respectively. The one-way and probabilistic sensitivity analyses confirmed the results of base case scenario. Based on this cost-effectiveness model, diclofenac 3% in HA can be considered the treatment of choice for AK lesions and surrounding field under a pharmacoeconomic point of view.
Lingua originaleEnglish
pagine (da-a)573-581
Numero di pagine9
RivistaGiornale Italiano di Dermatologia e Venereologia
Stato di pubblicazionePubblicato - 2010


  • Administration, Topical
  • Aminolevulinic Acid
  • Aminoquinolines
  • Cost-Benefit Analysis
  • Decision Trees
  • Delivery of Health Care
  • Diclofenac
  • Health Care Costs
  • Humans
  • Italy
  • Keratosis, Actinic


Entra nei temi di ricerca di 'Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system'. Insieme formano una fingerprint unica.

Cita questo